NCT03307629View on ClinicalTrials.gov

Safety and Tolerability of NOX66 in Combination With Palliative Radiotherapy in Patients With Late-Stage Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 1, 2017

Primary Completion Date

December 1, 2019

Study Completion Date

September 15, 2020

Conditions
Cancer
Interventions
DRUG

NOX66

NOX66 delivered as rectal suppository.

RADIATION

Irradiation Therapy

Radiation per selected tumour lesion.

Trial Locations (10)

2060

Genesis Cancer Care Mater Hospital, Sydney

2290

Genesis Cancer Care - Newcastle, Newcastle

2340

North West Cancer Centre, Tamworth Hospital, Tamworth

2800

Central West Cancer Care Centre - Orange Health Service, Orange

4215

Radiation Oncology Centres Gold Coast, Gold Coast

8013

Canterbury Urology Research Trust, Christchurch

0112

Research Institute of Clinical Medicine, Tbilisi

0141

TSMU The First University Clinic, Tbilisi

0144

National Center of Urology, Tbilisi

0186

Institute for Personalised Medicine, Tbilisi

Sponsors

Lead Sponsor

Noxopharm Limited
All Listed Sponsors
lead

Noxopharm Limited

INDUSTRY